Shift Pharmaceuticals
  • Home
  • About Shift
  • Shift’s Pipeline
  • Shift’s Technology
  • Shift News
  • Contact
Select Page
FDA grants Orphan Drug status for Shift’s lead compound for SMA

FDA grants Orphan Drug status for Shift’s lead compound for SMA

by Steve Oconnor | May 14, 2020 | Shift News Updates

Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA. Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to treat all forms of spinal...
Shift Pharmaceuticals partners with CMT Research Foundation to  further research CMT1A treatment

Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A treatment

by Steve Oconnor | Apr 18, 2020 | Shift News Updates

CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals to further research in...
Shift Pharmaceuticals partners with CMT Research Foundation to  further research CMT1A treatment

Shift Pharmaceuticals receives funding from Congressional Directed Medical Research Program (CDMRP)

by Steve Oconnor | May 19, 2019 | Shift News Updates

Overland Park: Shift Pharmaceuticals is pleased to announce the Company has been awarded a grant through the Congressional Directed Medical Research Program (CDMRP) to further the development of their initial drug candidate (E1v1.11) for the treatment of Spinal...
  • Facebook
  • Twitter